Publication Month: Sep 2020 | Report Code: TIPRE00005408 | No. of Pages: 175 | Category: Pharmaceuticals | Status: Published
Constipation is a commonly seen health condition among all age groups across the world. According to the article ‘Chronic Constipation’ published in May 2018, worldwide, the prevalence of constipation is estimated to be 16%. It is estimated to be varying between 0.7% to 79%. Also, the prevalence of constipation is higher among people age 60 years and above. The attributed prevalence of constipation to this age group is 33.5%.
Several factors are associated with the rising prevalence among older people, which include lack of normal bowel movements due to progressive age, improper diet and fluid intake, and inadequate physical activity. Whereas, among adults, the common cause of constipation is stress, lack of exercise, endocrine disorders, colon diseases, neurological dysfunction, and other causes such as environmental and pharmaceutical conditions.
The prevalence of constipation across the world varies substantially due to the different ethnic groups and perceptions. For instance, according to the article ‘What is the worldwide prevalence of constipation?’ published in March 2020, in North America, ~63 million people are affected by chronic constipation. Likewise, ~12% of people across the world live with self-defined constipation. The data also stated that people in the Americas and the Asia Pacific the prevalence is twice the European region. Constipation causes psychological morbidity and results in low quality of life. Thus, it essential to diagnose, manage, and treat constipation is very important. Therefore, the rising prevalence of constipation is expected to drive the demand for medicines treating constipation, further lead to the growth of the market.
Based on therapeutic, the constipation treatment market is segmented into laxatives, chloride channel activators, peripherally acting mu-opioid receptor antagonists, GC-C agonists, and 5-HT4 receptor agonists. The laxatives segment held the largest share of the market in 2019. However, GC-C agonists segment is anticipated to register the highest CAGR in the market during the forecast period.
Based on disease, the constipation treatment market is segmented into chronic idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation. The chronic idiopathic constipation segment held the largest share of the market in 2019, and is estimated to register the highest CAGR in the market during the forecast period.
Based on distribution channel, the constipation treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment held the largest share of the market in 2019, and is estimated to register the highest CAGR of 6.4% in the market during the forecast period.
|Market Size Value in||US$ 8,533.89 Million in 2019|
|Market Size Value by||US$ 13,386.19 Million by 2027|
|Growth rate||CAGR of 5.9% from 2020-2027|
|No. of Pages||175|
|No. of Tables||72|
|No. of Charts & Figures||69|
|Historical data available||Yes|
|Segments covered||Therapeutic ; Disease ; Distribution Channel , and Geography|
|Regional scope||North America, Europe, Asia Pacific, Middle East & Africa, South & Central America|
|Country scope||US, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Free Sample Copy Available|
Inorganic strategies such as partnerships, mergers, and acquisitions are commonly adopted by companies to cater to changing customer demand worldwide, which also allows them to maintain their brand name. The constipation treatment market players have been adopting organic strategies such as product launches and expansions to expand their footprint and product portfolios.
The List of Companies - Constipation Treatment Market